Literature DB >> 21684216

Overexpression of GDNF in the uninjured DRG exerts analgesic effects on neuropathic pain following segmental spinal nerve ligation in mice.

Kumiko Takasu1, Atsushi Sakai, Hideki Hanawa, Takashi Shimada, Hidenori Suzuki.   

Abstract

UNLABELLED: Glial cell line-derived neurotrophic factor (GDNF), a survival-promoting factor for a subset of nociceptive small-diameter neurons, has been shown to exert analgesic effects on neuropathic pain. However, its detailed mechanisms of action are still unknown. In the present study, we investigated the site-specific analgesic effects of GDNF in the neuropathic pain state using lentiviral vector-mediated GDNF overexpression in mice with left fifth lumbar (L5) spinal nerve ligation (SNL) as a neuropathic pain model. A lentiviral vector expressing both GDNF and enhanced green fluorescent protein (EGFP) was constructed and injected into the left dorsal spinal cord, uninjured fourth lumbar (L4) dorsal root ganglion (DRG), injured L5 DRG, or plantar skin of mice. In SNL mice, injection of the GDNF-EGFP-expressing lentivirus into the dorsal spinal cord or uninjured L4 DRG partially but significantly reduced the mechanical allodynia in association with an increase in GDNF protein expression in each virus injection site, whereas injection into the injured L5 DRG or plantar skin had no effects. These results suggest that GDNF exerts its analgesic effects in the neuropathic pain state by acting on the central terminals of uninjured DRG neurons and/or on the spinal cells targeted by the uninjured DRG neurons. PERSPECTIVE: This article shows that GDNF exerts its analgesic effects on neuropathic pain by acting on the central terminals of uninjured DRG neurons and/or on the spinal cells targeted by these neurons. Therefore, research focusing on these GDNF-dependent neurons in the uninjured DRG would provide a new strategy for treating neuropathic pain. Copyright Â
© 2011 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21684216     DOI: 10.1016/j.jpain.2011.04.003

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  15 in total

Review 1.  Mechanisms of acupuncture-electroacupuncture on persistent pain.

Authors:  Ruixin Zhang; Lixing Lao; Ke Ren; Brian M Berman
Journal:  Anesthesiology       Date:  2014-02       Impact factor: 7.892

2.  Augmenting glial cell-line derived neurotrophic factor signaling to treat painful neuropathies.

Authors:  Ahmet Höke
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-28       Impact factor: 11.205

3.  Glial cell line-derived neurotrophic factor-mediated enhancement of noradrenergic descending inhibition in the locus coeruleus exerts prolonged analgesia in neuropathic pain.

Authors:  M Kimura; A Sakai; A Sakamoto; H Suzuki
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

4.  Upregulated glial cell line-derived neurotrophic factor through cyclooxygenase-2 activation in the muscle is required for mechanical hyperalgesia after exercise in rats.

Authors:  Shiori Murase; Etsuji Terazawa; Kenji Hirate; Hiroki Yamanaka; Hirosato Kanda; Koichi Noguchi; Hiroki Ota; Fernando Queme; Toru Taguchi; Kazue Mizumura
Journal:  J Physiol       Date:  2013-04-15       Impact factor: 5.182

5.  Exercise-mediated improvements in painful neuropathy associated with prediabetes in mice.

Authors:  Anna L Groover; Janelle M Ryals; Brianne L Guilford; Natalie M Wilson; Julie A Christianson; Douglas E Wright
Journal:  Pain       Date:  2013-08-06       Impact factor: 6.961

6.  TRPV1 and TRPV4 play pivotal roles in delayed onset muscle soreness.

Authors:  Hiroki Ota; Kimiaki Katanosaka; Shiori Murase; Makiko Kashio; Makoto Tominaga; Kazue Mizumura
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

7.  Analgesia for neuropathic pain by dorsal root ganglion transplantation of genetically engineered mesenchymal stem cells: initial results.

Authors:  Hongwei Yu; Gregory Fischer; Allison D Ebert; Hsiang-En Wu; Xiaowen Bai; Quinn H Hogan
Journal:  Mol Pain       Date:  2015-02-12       Impact factor: 3.395

8.  A Novel Small Molecule GDNF Receptor RET Agonist, BT13, Promotes Neurite Growth from Sensory Neurons in Vitro and Attenuates Experimental Neuropathy in the Rat.

Authors:  Yulia A Sidorova; Maxim M Bespalov; Agnes W Wong; Oleg Kambur; Viljami Jokinen; Tuomas O Lilius; Ilida Suleymanova; Gunnar Karelson; Pekka V Rauhala; Mati Karelson; Peregrine B Osborne; Janet R Keast; Eija A Kalso; Mart Saarma
Journal:  Front Pharmacol       Date:  2017-06-21       Impact factor: 5.810

9.  Identification of key genes and pathways associated with neuropathic pain in uninjured dorsal root ganglion by using bioinformatic analysis.

Authors:  Chao-Jin Chen; De-Zhao Liu; Wei-Feng Yao; Yu Gu; Fei Huang; Zi-Qing Hei; Xiang Li
Journal:  J Pain Res       Date:  2017-11-14       Impact factor: 3.133

10.  Novel RET agonist for the treatment of experimental neuropathies.

Authors:  Hanna Viisanen; Ulpukka Nuotio; Oleg Kambur; Arun Kumar Mahato; Viljami Jokinen; Tuomas Lilius; Wei Li; Hélder A Santos; Mati Karelson; Pekka Rauhala; Eija Kalso; Yulia A Sidorova
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.